Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 11 September 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 11 September 2026 are set out below…
Choosing a new brand can be an exciting part of launching a product, service or business. Once the preferred name has gained internal support, however, commercial momentum can build quickly: domains are secured, packaging is commissioned, regulatory documentation is prepared and marketing plans begin to take shape.
Justice Rofe of the Federal Court of Australia has delivered another decision in the long-running dispute between Kutti Bay Investments Pty Ltd (formerly Jusand Nominees Pty Ltd) and Rattlejack Innovations Pty Ltd. Justice Rofe held that Kutti Bay’s application to amend three standard patents constituted an abuse of process, as it sought to overcome earlier Court decisions in the dispute.
Pearce IP Founder and CEO Naomi Pearce is one of four Australian IP professionals ranked by WIPR in Influential Women in IP 2026. Influential Women in IP is a global ranking celebrating women whose expertise, leadership and achievements are shaping the future of IP.
Pearce IP has achieved five individual recommendations in the Lexology Index – Australia & New Zealand 2026, with CEO and Founder Naomi Pearce and Executive Helen Macpherson both recognised across multiple categories. CEO and Founder, Naomi Pearce, has been ranked for IP – Patents, Life Sciences, and IP – Trade Mark Agents & Attorneys.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 August 2026 are set out below…
Australia. Preliminary Discovery. A New Frontier. Generics Are Now Using Preliminary Discovery in AU to Determine Whether to Mount Validity Challenges. Preliminary discovery applications are becoming increasingly common in the context of patent disputes in Australia.
The Full Court of the Federal Court of Australia (Justices Beach, Jackson and Jackman) has issued a further, and what appears to be the final, decision in the long-running litigation between Nalco Company (Nalco) and Cytec Industries Inc (Cytec).
Naomi Pearce, Pearce IP’s Founder, CEO and Executive, has again been recognised in the 2026 edition of IAM Strategy 300 for: Legal, and IP Management Consultancy. Naomi has been recognised by IAM Strategy 300 14 times since 2020.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 August 2026 are set out below…
In a significant PBS pricing decision, Justice Downes held that the PBS listing of Alphapharm’s generic Descovy® would also trigger statutory price reductions for several of Gilead’s related combination therapies, including Odefsey®, Biktarvy® and Genvoya®, under s 99ACC of the National Health Act.
Two of Pearce IP’s leaders have been recommended by the Lexology Index: Intellectual Property 2026 which honours a small number of leading IP lawyers across 88 countries. CEO and Founder, Naomi Pearce and Executive Helen Macpherson are is recommended for Patents, and Copyright respectively.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 14 August 2026 are set out below…
All of Pearce IP’s New Zealand Executives have been recognised in the 2026 Doyle’s Guide – Leading Intellectual Property Lawyers (New Zealand) rankings. Paul Johns is one of 11 lawyers honoured as a Leading Intellectual Property Lawyer. Sally Paterson is one of 21 lawyers recognised as a Recommended Intellectual Property Lawyer.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 August 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 31 July 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 July 2026 are set out below…
How do you protect confidential information before a former employee makes it public? Naomi Pearce and Helen Macpherson discuss a recent Federal Court decision which highlights how quickly Australia’s courts can act when IP rights are at risk.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 July 2026 are set out below…
Justice Stellios, sitting as duty judge in the Federal Court of Australia, has granted a mandatory interlocutory injunction requiring RedTail Technology Pty Ltd and its founder and sole director, secretary and shareholder (Richard Pahlavani).
The Full Court of the Federal Court of Australia has delivered its decision in NOCO’s appeal from the primary judge’s decision in The NOCO Company v Brown and Watson International Pty Ltd [2025] FCA 887. The Full Court has dismissed NOCO’s appeal, rejecting NOCO’s challenges on lack of inventive step and the correct priority date for assessing novelty.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 10 July 2026 are set out below…
Shanghai Lytone Biochemicals has failed in its opposition to the grant of Fresh Inset S.A.’s patent application for compositions and articles comprising complexes of 1-methylcyclopropene (1-MCP) and alpha-cyclodextrin (α-CD), which are used to prolong the shelf life of plant products by inhibiting the effects of ethylene.
Pearce IP is pleased to welcome Sarah Dieckmann as an Associate and Foreign Registered Patent Attorney, further strengthening the firm’s specialist capability in biotechnology and life sciences intellectual property.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.